Clinical trials: PBC, open to volunteers
Primary Biliary Cholangitis (PBC)
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) and cirrhosis (scarring of the liver). PBC is a slowly progressive disease, characterised by damage to the bile ducts in the liver, leading to a…
- Trial name
- ELFIDENCE (NCT06016842)
- Testing
- Elafibranor
- Where
- 198 sites in United States, Argentina and 26 more
- Volunteers
- 276 people
- Sponsor
- Ipsen
PBC
Study on Clinical and Pathological Features of Primary Biliary Cholangitis and Risk Factors Related to Disease Progression
Primary biliary cholangitis (PBC) is a chronic autoimmune intrahepatic cholestatic liver disease characterized by progressive, non-suppurative, destructive cholangitis, potentially leading to fibrosis, cirrhosis, and liver…
- Trial name
- NCT07733882
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Beijing Municipal Administration of Hospitals
Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC)
The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching
Cholestatic liver diseases are characterized by jaundice, pruritus, and elevated levels of alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT).
- Conditions
- Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Atopic Dermatitis (AD)
- Trial name
- NCT07678645
- Testing
- Upadacitinib 15 MG
- Where
- China
- Volunteers
- 44 people
- Sponsor
- RenJi Hospital
Primary Biliary Cholangitis (PBC)
Using Digital Health Technology to Monitor Patients With Primary Biliary Cholangitis (PBC)
The purpose of this study is to explore the use of digital health technology for measuring symptoms and daily health in people with primary biliary cholangitis (PBC).
- Trial name
- NCT07631442
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Primary Bilary Cirrhosis (PBC)
Clinical Characterization of Patients With Primary Biliary Cirrhosis Treated With Seladelpar in the Real-life Setting
The seladelpar registry will collect real-world data of patients with PBC diagnosis treated with seladelpar in the real-life scenario in Germany and Switzerland.
- Trial name
- SENSE registry (NCT07549607)
- Where
- 21 sites in Germany, Switzerland
- Volunteers
- 100 people
- Sponsor
- University of Leipzig
Primary Biliary Cholangitis (PBC), Primary Biliary Cholangitis
Biochemical Response and Clinical Outcomes in Patients With PBC
This study is a bidirectional cohort study. The investigators conduct a bidirectional cohort study utilizing a database in mainland China, continuously collecting demographics, clinical symptoms, and biochemical characteristics…
- Trial name
- NCT07449793
- Testing
- Only observation
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- RenJi Hospital
Primary Biliary Cholangitis (PBC)
Fenofibrate in Primary Biliary Cholangitis: a Real World Study
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Fenofibrate in Combination with Ursodeoxycholic Acid in Subjects with Primary Biliary Cholangitis (PBC)
- Trial name
- NCT06755151
- Testing
- Fenofibrate
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Primary Biliary Cholangitis (PBC)
Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Fenofibrate in Combination with Ursodeoxycholic Acid in Subjects with Primary Biliary Cholangitis (PBC)
- Trial name
- NCT06755541
- Testing
- Fenofibrate in Combination With Ursodeoxycholic Acid
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Primary Biliary Cholangitis (PBC)
FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy
The goal of this clinical trial is to learn if the drug Fenofibrate works to treat adults with a liver disease called Primary Biliary Cholangitis (PBC) who have not received previous treatment.
- Trial name
- NCT07296458
- Testing
- Fenofibrate, UDCA (Ursodeoxycholic acid)
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Primary Biliary Cholangitis (PBC)
A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics
About 1/3 of patients with primary biliary cholangitis (PBC) exhibit moderate to severe interface hepatitis, and this group of patients have poor response to UDCA treatment.
- Trial name
- NCT06591468
- Testing
- Prednisone, UDCA (Ursodeoxycholic acid)
- Where
- 2 sites in China
- Volunteers
- 244 people
- Sponsor
- Han Ying
Primary Biliary Cholangitis (PBC)
Early Diagnosis of Primary Biliary Cholangitis (PBC) in Patients With Positive Anti-Mitochondrial Antibodies (AMA) and Normal Alkaline Phosphatase (ALP)
The goal of this observational study is to achieve early diagnosis of Primary Biliary Cholangitis (PBC) in patients with positive Anti-Mitochondrial Antibodies (AMA) and Normal Alkaline Phosphatase (ALP) in adults aged 18-80…
- Trial name
- NCT07205874
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Hospital Universitario La Paz
Primary Biliary Cholangitis (PBC)
RELIEF: Multimodal Prehabilitation to Treat Fatigue in Patients With Primary Biliary Cholangitis
The implementation of a non-pharmacological multimodal intervention program-including physical exercise, nutritional counseling, and psychological support-is expected to improve fatigue in patients with primary biliary…
- Trial name
- RELIEF (NCT07161245)
- Testing
- Multimodal prehabilitation, standard of care
- Where
- Spain
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Hospital Clinic of Barcelona
Primary Biliary Cholangitis (PBC), Long-term Outcomes
PBC Long-term Outcomes Study
Primary biliary cholangitis (PBC) is an autoimmune liver disease predominantly affecting middle-aged women. While historically it was deemed rare, advancements in specific auto-antibody tests have led to increased recognition of…
- Conditions
- Primary Biliary Cholangitis (PBC), Long-term Outcomes, Prognosis, Multicenter Prospective Study
- Trial name
- NCT07149675
- Where
- China
- Volunteers
- 4,000 people
- Sponsor
- Beijing Friendship Hospital
PBC, Primary Biliary Cholangitis
Swiss Primary Biliary Cholangitis Cohort Study
Research project in which biological material is sampled and health-related medical data is collected. In addition, already existing health-related medical data are used for further research. Coded data are used.
- Trial name
- NCT03146910
- Where
- 13 sites in Switzerland
- Volunteers
- 500 people
- Sponsor
- Fondazione Epatocentro Ticino
the Rate of Participation in Screening for PBC
Experimentation With Screening for Bronchopulmonary Cancer and Primary Cardiovascular Prevention, Early Management of COPD and an Offer Exempted From Smoking Cessation
The study consists of recruiting a target population by sending a letter from the Regional Center for Cancer Screening in Ile de France.
- Trial name
- LUMASCAN-2 (NCT05440123)
- Testing
- screening for bronchopulmonary cancer
- Volunteers
- 300 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Hepatitis Autoimmune Disease, Primary Biliary Cholangitis (PBC)
Spanish Registry of Autoimmune and Cholestatic Liver Diseases (ColHai)
The purpose of the registry is to know the status of primary biliary colgantis, autoimmune hepatitis, primary sclerosing cholagitis and genetic cholestatic diseases in Spain.
- Conditions
- Hepatitis Autoimmune Disease, Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Cholestatic Genetic Diseases
- Trial name
- ColHai (NCT06767605)
- Where
- Spain
- Volunteers
- 5,000 people
- Sponsor
- Asociación Española para el Estudio del Hígado
Primary Bilary Cirrhosis (PBC), Autoimmune Hepatitis
Canadian Network for Autoimmune Liver Disease
CaNAL is a longitudinal observational cohort study of patients diagnosed with Primary Biliary Cholangitis (PBC), Autoimmune Hepatitis (AIH), or overlap syndrome.
- Conditions
- Primary Bilary Cirrhosis (PBC), Autoimmune Hepatitis, Overlap Syndrome
- Trial name
- CaNAL (NCT03569826)
- Testing
- Observational; no intervention
- Where
- 15 sites in Canada
- Volunteers
- 2,500 people
- Sponsor
- University Health Network, Toronto